SLC25A13 and colorectal carcinoma: Miyo et al. reported that glutamine dehydrogenase 1 (GLUD1) and SLC25A13 (a mitochondrial aspartate-glutamate carrier) played an essential role in cell survival of CRC cells under glucose-deprived conditions, and that combined expression of GLUD1 and SLC25A13 was significantly associated with tumor aggressiveness and poorer prognosis in CRC patients [13].